Cannabis is not a proven first-line treatment for chronic insomnia. A few small trials of specific cannabinoid products have reported better sleep symptoms, but results vary by formulation and outcome. Studies that measure brain activity or movement during sleep often tell a less convincing story than ratings of how well someone felt they slept 1 2.
That distinction matters. Feeling drowsy is not the same as correcting insomnia, and a change in rapid eye movement (REM) sleep is not automatically a benefit. It is also inaccurate to treat cannabis flower, a CBD oil, a CBN gummy, and a standardized THC-containing study extract as versions of the same treatment.
Cannabis is not one sleep treatment
Cannabis contains many compounds, but most sleep claims focus on tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabinol (CBN). The evidence for each is different.
| Product or compound | What it means in sleep research | Main limitation |
|---|---|---|
| THC-containing cannabis | THC is intoxicating and can alter attention, coordination, perception, and sleep physiology. Studies use different amounts, routes, and combinations. | A result from one THC formulation does not predict the effect of flower, a vape, an edible, or another extract. |
| CBD | CBD does not produce the typical THC high, but it is pharmacologically active. It can cause drowsiness or other side effects, affect medicines, and injure the liver in some circumstances. | Controlled insomnia evidence has not established a reliable sleep benefit from CBD alone 3 4. |
| CBN | CBN is marketed as a sedating cannabinoid. Human insomnia research is only beginning to test that claim. | A recent objective insomnia trial was small and single-night, and its primary outcome did not improve significantly 5. |
| Standardized cannabinoid medicine or study extract | Researchers can define the exact cannabinoids, concentrations, route, and manufacturing controls. | The finding applies to that studied product and schedule, not to an untested retail product. |
| Whole-plant or retail cannabis | Potency, cannabinoid balance, route, and manufacturing oversight can differ substantially. | Product labels such as “indica,” “sativa,” or “sleep” do not establish clinical efficacy. |
The FDA has approved a purified CBD medicine for certain seizure disorders and synthetic cannabinoid medicines for limited indications. These approvals do not include insomnia. Retail CBD and state-dispensary cannabis products have not gone through the same federal review for sleep efficacy, dose, interactions, and manufacturing quality 4 6.
What controlled insomnia studies have found
The strongest way to read this evidence is formulation by formulation, without turning an early signal into a recommendation.
A small THC, CBD, and CBN extract trial found short-term improvements
A 2021 randomized crossover trial tested a standardized sublingual extract called ZTL-101 in 24 adults with chronic insomnia symptoms. The extract contained THC, CBN, and CBD in a fixed ratio. After two weeks, participants reported lower insomnia severity and longer sleep than with placebo. Wrist actigraphy also found modest changes, including more total sleep time and less wake time after sleep onset 7.
The study does not establish that cannabis generally treats insomnia. Only 23 people completed it, treatment lasted two weeks, and Zelira Therapeutics sponsored the trial. Seventeen participants reported at least one adverse event while taking the extract. Laboratory polysomnography did not find a significant improvement in sleep duration, quality, or sleep-stage proportions. The result is a promising signal for one specific formulation, not evidence for a strain, gummy, vape, or long-term nightly use 7.
CBD alone did not improve the main insomnia outcomes
A 2024 pilot trial assigned 30 adults with moderate to severe insomnia to 150 mg of sublingual CBD or placebo each night for two weeks. Insomnia severity, self-reported time to fall asleep, time awake during the night, and sleep efficiency did not differ between groups. The CBD group had a temporary objective sleep-efficiency finding and some measures of well-being or morning functioning improved, but most sleep outcomes did not 3.
The amount used in that trial is a research detail, not a suggested dose. Consumer CBD products may contain different ingredients or amounts, and the FDA has not established a safe or effective over-the-counter CBD dose for insomnia 4.
CBN has early, mixed evidence
A 2026 randomized crossover trial tested single oral doses of CBN in 20 adults with diagnosed insomnia. Neither the 30 mg nor 300 mg dose significantly improved the primary outcome, wake time after sleep onset. The higher dose improved some secondary measures, including self-reported sleep quality and time to fall asleep, but this was one laboratory night in a very small group. It cannot establish sustained benefit or support choosing a retail CBN product 5.
One acute THC and CBD study reduced total and REM sleep
Another pilot trial studied one oral dose containing 10 mg THC and 200 mg CBD in 20 adults with insomnia. Compared with placebo, the combination reduced total sleep time by about 25 minutes and REM sleep by about 34 minutes. Participants did not report better sleep quality. Objective alertness, cognition, and simulated driving were not different when measured at least nine hours later, although participants reported a small increase in sleepiness 8.
This single-dose result should not be used as a driving clearance rule. It tested one product in a small, screened group under controlled conditions. It also shows why the common claim that cannabis simply creates “deeper sleep” is too broad.
The overall evidence is mixed
A 2025 meta-analysis of six randomized trials, involving 1,077 participants with and without insomnia or poor sleep, found an improvement in self-reported sleep quality across cannabinoid interventions. The studies differed greatly from one another, which reduces confidence in a single pooled estimate. CBD-only treatments did not show a significant benefit in the subgroup analysis 1.
A separate 2025 review focused on objective sleep architecture. Across 18 studies, cannabis did not consistently change total sleep time, time to fall asleep, wake time, sleep efficiency, or sleep stages. Earlier claims that THC reliably suppresses REM sleep came largely from small studies using high THC amounts. Newer results were mixed 2.
Taken together, these reviews do not prove that nobody experiences a benefit. They show that the benefit is not predictable across products or people, and that subjective improvement can occur without a clear, consistent change in measured sleep.
Why subjective sleep and measured sleep can disagree
Insomnia is partly defined by a person's experience, so self-reported sleep is important. Polysomnography and actigraphy answer different questions.
- A sleep diary records perceived time to fall asleep, awakenings, restfulness, and daytime effects.
- Actigraphy estimates sleep and wake from movement over several nights, but quiet wakefulness may be counted as sleep.
- Polysomnography measures brain activity, eye movements, muscle activity, breathing, and sleep stages during a monitored night.
A person can feel that cannabis helped because they felt less distressed, became drowsy, or remember fewer awakenings. That experience does not necessarily mean they slept longer, had more restorative sleep, or treated the process maintaining their insomnia. The reverse can also occur: a small objective change may not feel meaningful.
This is why a credible claim should name the outcome. “Participants reported better sleep” is not the same as “polysomnography showed longer sleep.”
Pain-related sleep findings are not insomnia findings
Some of the more favorable cannabinoid sleep evidence comes from people treated for chronic pain. A 2021 systematic review of randomized trials found that non-inhaled medical cannabis or cannabinoids produced a small improvement in sleep quality among people with chronic cancer or non-cancer pain. The same review found increased dizziness, drowsiness, impaired attention, nausea, and transient cognitive effects 9.
These results may reflect pain relief, sedation, or both. They do not show that cannabis treats insomnia disorder in someone whose main problem is not pain. They also do not apply automatically to smoked or vaped products, which were not represented in the review.
Regular use, tolerance, and withdrawal can blur the picture
Most insomnia trials have lasted one night to a few weeks, so they cannot establish durable benefit from nightly use. The objective sleep review found a clearer pattern during withdrawal than during active use: stopping after regular use was consistently associated with longer sleep onset, less total sleep, and REM rebound 2.
REM rebound can bring more vivid or intense dreams. Withdrawal-related insomnia can also make restarting cannabis feel like proof that it is treating the original sleep problem, when it may partly be relieving symptoms created by stopping.
Some people develop cannabis use disorder. Signs include using more than intended, unsuccessful efforts to stop, craving, continuing despite problems, giving up important activities, using in risky situations, needing more for the same effect, or having symptoms when stopping. Risk is higher with more frequent use and when use begins in adolescence 10.
If sleep becomes much worse whenever you try to stop, or cannabis use feels difficult to control, discuss both issues with a clinician. Abruptly changing a prescribed cannabinoid medicine should also be discussed with the prescriber.
Route and product quality change the risk
The way a product is used changes how quickly and predictably its effects appear. It does not turn an unproven sleep treatment into a proven one.
- Smoked products: Smoke exposes the lungs and people nearby to harmful chemicals. A fast perceived effect does not make smoking a safer sleep route.
- Vaped products and concentrates: These may deliver high THC concentrations and can contain additives or contaminants. Vaping has also been linked to serious lung injury 6.
- Edibles and drinks: Effects can be delayed and unpredictable, increasing the chance of taking more before the first amount is fully felt 6.
- Oils and sublingual products: These were used in several insomnia trials, but a retail oil is not equivalent to a standardized study extract.
“Indica” and “sativa” are not evidence-based insomnia prescriptions. Terpenes may affect aroma and could have biological effects, but high-quality clinical trials have not shown that a strain label or terpene profile can reliably select an effective insomnia treatment.
Product quality adds another uncertainty. FDA testing has found CBD products that did not contain the claimed amount, and the agency has investigated reports of contaminants such as pesticides, heavy metals, and THC. A certificate of analysis may provide useful batch information, but it does not prove that a product treats insomnia or is risk-free 4.
Safety concerns to consider
Driving and next-day impairment
THC can slow reaction time, impair coordination, distort perception, and affect judgment. The relationship between a measured THC concentration and an individual person's driving impairment is not simple. Do not use how rested you feel, a home test, or a fixed number of hours as proof that you can drive safely 6.
If you need to drive or operate machinery, the safest choice is not to use an impairing cannabis product. Arrange another driver if there is any doubt. Local impaired-driving laws may apply even where adult cannabis use is legal.
Alcohol, sedatives, and other medicines
Alcohol and cannabis together generally produce more impairment than either alone. CBD can add to drowsiness from alcohol or medicines that slow brain activity, including some medicines used for anxiety or sleep. Cannabis products may also change how prescription medicines work 6 4.
Do not assume a non-intoxicating label means no interaction. Ask a pharmacist or prescriber to review the exact product and all medicines, especially sleep medicines, benzodiazepines, opioids, seizure medicines, blood thinners, and medicines with important liver metabolism. Do not stop a prescription on your own.
CBD, liver injury, and drug metabolism
The FDA warns that CBD can injure the liver and can raise or lower the effects of other medicines. Much of the detailed safety information comes from prescription CBD, where clinicians can monitor blood tests and interactions. It is unclear how those risks translate across unapproved consumer products, amounts, and patterns of use 4.
That warning is specific to CBD evidence. It should not be rewritten as a claim that every cannabinoid product causes liver injury. People with liver disease or several prescriptions need an individualized medication review before using CBD.
Mental health and cannabis use disorder
THC can cause anxiety, panic, paranoia, disorientation, or hallucinations. Cannabis use is associated with psychosis and schizophrenia, with a stronger association among people who begin younger or use more frequently. It is also associated with depression, social anxiety, and suicidal thoughts, although an association alone does not prove that cannabis caused an individual's condition 11.
A personal or family history of psychosis, bipolar disorder, severe anxiety reactions, or substance use disorder deserves particular caution and a clinician-led discussion. Cannabis should not be used to self-treat a new psychiatric symptom.
Pregnancy, breastfeeding, adolescents, and older adults
ACOG advises stopping cannabis during pregnancy and lactation and states that there are no medical indications for cannabis use during pregnancy or the postpartum period. THC and other cannabis chemicals can reach a developing fetus or an infant, and evidence is not sufficient to establish a safe product, route, or amount 12.
Adolescents face higher risks from frequent use, including cannabis use disorder and effects on attention, memory, and learning. Sleep difficulty in a child or teenager should be assessed without treating cannabis as an over-the-counter sleep aid 10 6.
Older adults are more likely to have fall risk, cognitive vulnerability, and several medicines. Dizziness, drowsiness, and impaired attention therefore have greater practical consequences, and the small insomnia trials do not establish safety for frail older adults 9. A medication and fall-risk review is more useful than relying on “low dose” or “CBD only” as a safety guarantee.
Legal status depends on the product and location
Cannabis rules can differ by country, state, territory, tribe, product type, age, medical authorization, and activity. Federal and state rules in the United States do not always align, and the federal scheduling process has continued to change 13.
Check current official rules where you live and where you plan to travel. Also check workplace, professional-license, housing, and sports policies. A product being sold locally does not establish that it is legal to carry across a border, safe to drive after using, or permitted by an employer.
What to do about ongoing insomnia
For chronic insomnia, the American Academy of Sleep Medicine gives a strong recommendation to multicomponent cognitive behavioral therapy for insomnia. CBT-I is more than general sleep-hygiene advice. It uses a structured plan to change the behaviors and thought patterns that keep insomnia going 14.
A clinical assessment can also look for a condition that needs different treatment, such as sleep apnea, restless legs syndrome, circadian-rhythm disruption, pain, medication effects, depression, anxiety, or substance withdrawal. Cannabis may mask sleepiness without addressing one of these causes.
Seek an assessment if sleep difficulty is persistent, affects daytime safety or function, or has led to regular reliance on cannabis, alcohol, or another sedating substance. Bring the product label or a photo of it, how often you use it, the route, and a complete medicine list.
When to get urgent help
Call emergency services if someone who used cannabis:
- Cannot be woken normally, collapses, has a seizure, or has trouble breathing
- Has chest pain, faints, or is dangerously agitated or confused
- Has hallucinations, paranoia, or behavior that creates an immediate risk of harm
- Has suicidal thoughts with immediate danger or cannot stay safe
Contact a local poison center promptly after accidental ingestion by a child, or when the product or amount is unknown. Severe or persistent vomiting, dehydration, worsening confusion, or a reaction that is not settling also needs urgent medical advice 6.
Bottom line
Cannabis can make some people feel sleepy, and a few short trials of specific cannabinoid formulations have found better self-reported insomnia symptoms. The wider evidence does not show a consistent improvement in objective sleep, CBD alone has not demonstrated reliable insomnia benefit, and long-term nightly efficacy remains uncertain.
The safest interpretation is specific: name the cannabinoid, formulation, route, amount, population, outcome, and duration that were actually studied. Do not turn that finding into a recommendation for a retail product. For persistent insomnia, start with a proper assessment and evidence-based treatment such as CBT-I, while treating cannabis use, interactions, and withdrawal as part of the clinical picture.
